Journal of Cancer Research and Clinical Oncology · 2018 · 14 citations · 19 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyMolecular OncologyCheckpoint Inhibitor TherapyHematologic Malignancy TherapyLymphoid NeoplasmsLymphoid TumorsTyrosine Kinase InhibitorsAnaplastic Lymphoma Kinase InhibitorsBtk InhibitorsLymphoma ChemotherapyLymphoma PathogenesisLymphoma Treatment Response
19
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang, Simon Rule, Peter Martin et al. · New England Journal of Medicine · 2013 · 1.7K citations · Full text
Medicine, Hematology, Pharmacology +17
Lee Honigberg, Ashley M. Smith, Mint Sirisawad et al. · Proceedings of the National Academy of Sciences · 2010 · 1.5K citations · Full text
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Jennifer A. Woyach, Richard R. Furman, Ta-Ming Liu et al. · New England Journal of Medicine · 2014 · 1.3K citations · Full text
Medicine, Oncology, Pharmacology +14
Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase
Zhengying Pan, Heleen Scheerens, Shyr‐Jiann Li et al. · ChemMedChem · 2006 · 675 citations